[Closed] EUnetHTA 21 launches Open Call for JSC

EUnetHTA 21 is launching the first Open Call for applications from the pharmaceutical industry for four Joint Scientific Consultations (JSC), starting in January 2022. These will be consultations in parallel to EMA scientific advice and hence will focus on medicinal products. The Open Call will remain open from 8 November, 2021 to 7 December, 2021. […]

EUnetHTA 21 – first Stakeholder Kick-Off Meeting

EUnetHTA 21 Secretariat is pleased to announced that the first EUnetHTA 21 Stakeholder Kick-Off Meeting is scheduled, online, for 03.12.2021 at 10:30-12:00 CET.  The meeting will entail a high-level focus and will address the following points:  Introduction of the ‘new’ EUnetHTA 21 as a consortium;  Our governance principles;  Planned Stakeholder interaction (public consultations);  Presentation of the deliverables planned over the course of […]

Engaging Stakeholder in Joint Action 3 – now available for access

​​As Joint Action 3 (JA3) comes to a close, an overview of stakeholder interaction has been prepared that focusses on who our stakeholders are, the product-related progress we have made, and all related stakeholder activities through JA3.  Access here: Engaging Stakeholders in Joint Action 3​

2021 EUnetHTA Forum Welcome Guide

The 2021 EUnetHTA Forum Welcome Guide is now available. The guide forms a comprehensive overview of EUnetHTA activities as we near completion of Joint Action 3, and is recommended reading prior to the Forum on 15 April. Follow the link, or check the ‘Get Involved’ dropdown menu on our homepage and then to ‘Events’, you’ll […]

2021 EUnetHTA Forum – Agenda

The 2021 EUnetHTA Forum takes place online on 15th April. In advance of this, please follow the link to access the agenda for the day’s events and speakers. 2021 EUnetHTA Forum Agenda Also, if you were unable to register and still wish to do so, please contact us directly at eunethta@zinl.nl See you there! EUnetHTA […]

Recommendations for Horizon Scanning, Topic Identification, Selection and Prioritisation for European Cooperation on Health Technology Assessment now available

​The final report ‘Recommendations for Horizon Scanning, Topic Identification, Selection and Prioritisation for European Cooperation on Health Technology Assessment’ is now available. The draft recommendations were under consultation during the period July–September 2018. An overview and response to the feedback during the consultation is available, together with Endpoint Evaluations for both Pharmaceuticals and Other Technologies. […]

EUnetHTA Magazine – Winter 2020 – Now Available

We are pleased to publish the Winter 2020 issue of EUnetHTA Magazine, our quarterly update on HTA with input from network stakeholders. As always, we welcome your feedback so we can continue to improve how we can focus on developments in HTA. Happy reading! Click here for more.  

PTJA05 – enasidenib for the treatment of adult patients with relapsed or refractory acute myeloid leukaemia (AML) with an isocitrate dehydrogenase 2 (IDH2) mutation

On 6 Dec 2019, Celgene officially notified the Committee for Medicinal Products for Human Use (CHMP) that it wishes to withdraw its application for a marketing authorisation for enasidenib. Since no CHMP opinion will be granted at this stage, EUnetHTA closed this Joint Assessment on 12 Dec 2019. The final Project Plan for the applied […]

EUnetHTA 2020 Forum

The EUnetHTA 2020 Forum was originally planned to be held on 2nd April at Zorginstituut Nederland (ZIN), the Dutch Health Care Institute, in Diemen near Amsterdam. However, due to the ongoing Covid-19 pandemic, the Forum had to be postponed. in light of this, we are, however, pleased to offer the accompanying Welcome Guide that was […]